65 results about "Immunoliposome" patented technology

Methods of preparing targeting ligand bound avidin-lipid vesicles for use in preparing a targeted, therapeutic liposome composition are disclosed. Each vesicle comprises an avidin molecule coupled to the polymer-conjugated biotin which retains multiple free site biotin-binding sites such that the vesicle may be used to further couple a biotinylated-targeting ligand.

The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab' domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.

A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.

The present invention provides methods of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprising (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex. The present invention also provides cationic immunoliposome or polymer complexes produced by such methods and compositions comprising such complexes. The present invention also provides methods for treating various diseases and disorders, including cancers, by administering the complexes and compositions of the invention to a patient.

Immunoliposomes and use thereof in highly specific and sensitive nucleic acid amplification assays relying on amplification of specific nucleic acid sequences released from encapsulation within a liposome after a receptor on the liposome couples with a targeted analyte / antigen immobilized on a select surface. The immunoliposome nucleic acid amplification assay permits both quantitative and qualitative analyte detection.

An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

The invention relates to an immunoliposome biochip, a preparation method thereof and an application thereof in biological detection. The immunoliposome provided by the invention is distributed on the chip in a micro-array way, and includes molecule probes, such as molecular beacon with fluorescence; and outside of the immunoliposome is loaded with various ligands. The immunoliposome biochip can specifically capture target cells in a cell mixture, and ensure messenger RNA and / or micromolecule RNA in the target cells without destroying biomarkers in the cells. In addition, the immunoliposome biochip provided by the invention can be used for capturing and selecting nanoparticles secreted by virus and cells, such as micro bubbles and exosomes. The immunoliposome biochip has advantages of simple operation, low cost, rapidness, sensitive and high selectivity, and can be used for molecular detection of various diseases, food safety and other fields.

A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.

Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.

The present invention relates to an immunoliposome preparation having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.

The invention, belonging to the technical field of medicament, relates to an immuno liposome with pulmonic target activity and a preparation method thereof. The immuno liposome disclosed herein comprises pulmonic surfactant protein (SP) A polyclonal antibody, actie pharmaceutical ingredients and a nano liposome, wherein, dexamethasone sodium phosphate (DXM) and other glucocorticoids are used as the actie pharmaceutical ingredients, the nano liposome is used as a carrier, and the SP-A polyclonal antibody is used as a specific pulmonic targeted agent. The immuno nano liposome disclosed herein has the advantages of definite pulmonic target activity, and efficient and stable realization of the targeted conveying of the actie pharmaceutical ingredients to lung, so that maximum concentration ofDXM in the lung is increased by 5.08 times compared with common medicines, and the area under curve when 12 hours after injecting the medicine is increased by 40.21 times. According to the invention,the dosage of glucocorticoids can be reduced, the curative effect on lung diseases can be improved, and systematic side effect can be reduced at the same time. The invention has new values for clinicapplication.

The present invention provides targeted delivery systems to deliver pharmaceuticals to irradiated tissue comprising a biomolecule carrier, a targeting moiety to cellular adhesion molecules and a pharmaceutical. The present invention also provides methods of selectively targeting endothelial tissue for delivery of a pharmaceutical thereto and of treating a pathophysiological state in an individual using the targeted delivery systems disclosed herein. Further provided is a method of optimizing an immunoliposome for specific targeting of a pharmaceutical encapsulated therein to irradiated tissue by selecting a liposome that has a greater rate of adhesion to the irradiated tissue than a rate of uptake by the reticuloendothelial system.

An immunoliposome composition comprised of liposomes bearing a ligand for targeting to cells expressing a growth factor receptor, such as HER2, is described. Binding of the immunoliposome to HER2-expressing cells results in internalization of the immunoliposome for cytoplasmic delivery of an entrapped drug.

A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.

The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.

The invention provides a method for a multi-layered lipid particles in the form of liposomes that are coated first with a cryoprotectant followed by a targeting moiety over the coat of cryoprotectant, and a method for encapsulating drugs and agents in the multi-layered coated liposomes. In addition, ready-to-use liposome kits for coating with targeting agent of choice and for drug and / or agent encapsulation.

The invention provides an immunoliposome of a CD19 monoclonal antibody. First, a film dispersion method is adopted to prepare the cubical space stable norcantharidin immunoliposome, wherein the mole ratio of soy bean lecithin, cholesterol, methoxyl-polyethylene glycol 2000-phosphatidyl ethanolamine is 2:1:0.01, the mass ratio of norcantharidin immunoliposome and soy bean lecithin is 1:20, and entrapment efficiency of high-performance liquid detection NCTD is 46.5+ / -2.21%. The research proves that 2E8-SL-PE can be combined with Nalm-6 and Raji cell specifically, the positive rates thereof are respectively 89.44% and 88.73%, the 2E8-SL-PE is almost not combined with Molt-3 and K562 cell with the positive rates being only 1.95% and 1.39%, which shows that the immunoliposome has obvious target recognition effect. The norcantharidin immunoliposome can be applied in preparing specific target killer B lymphocyte leukemia and stem cell drugs thereof.

Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.

The invention discloses a liposome medicinal composition with tumor targeting, in-vivo tracing and treating functions and a preparation method thereof. The medicinal composition is a liposome targeting medicament which is resistant to CD44 antibody coupling, has a molecular imaging function simultaneously, and can be used for monitoring the in-vivo distribution of a medicament in real time in a living body state. In particular, plasmids containing three fusion genes, including renilla luciferase, red fluorescent proteins and suicide gene thymidine kinase, are coupled to CD44 antibody mediation-resistant immunoliposome, the specificity of liposome nanoparticles in a liver cancer in-situ model of an in-vivo targeting NOD / SCID (Non-Obese Diabetic / Severe Combined Immune-Deficiency) mouse is monitored by detecting a renilla luciferase signal with a living body imaging system, and apoptosis of liver cancer cells is induced by applying target thymidine kinase of ganciclovir; and moreover, a targeted liposome can be coated with adriamycin for inducing apoptosis of the liver cancer cells. The liposome medicinal composition provided by the invention does not have any toxic or side effect, has small damage and a good effect, and is suitable to be applied for a long time.

An immunoliposome composition targeted to the alpha-V-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha-V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or a the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

The invention discloses immunoliposome based on endostatin genes, a preparation method and the application thereof. The immunoliposome comprises Vasohibin gene recombination eukaryotic expression vector, liposome and anti-eighth factor-associated antigen monoclonal antibody; wherein the liposome internally wraps up the Vasohibin gene recombination eukaryotic expression vector; the surface of the liposome is connected with the anti-eighth factor-associated antigen monoclonal antibody; the preparation method thereof comprises three steps of: the construction of the Vasohibin gene recombination eukaryotic expression vector, the preparation of the liposome wrapping up the Vasohibin gene recombination eukaryotic expression vector, and the connection of the liposome wrapping up the Vasohibin gene recombination eukaryotic expression vector and the anti-eighth factor-associated antigen monoclonal antibody. The immunoliposome can particularly act on vascular endothelial cells of the lung to inhibit the vasculogenesis and pulmonary fibrosis formation, has strong targeting effect, little side effect and can be used for preparing anti-fibrosis drugs.

An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

The invention relates to a biotinylated liposome used for detecting pancreas cancer marker REG1A. The biotinylated liposome used for detecting pancreas cancer marker REG1A comprises coated reporter DNA fragments, and PEG-200 surface modified biotin; according to the preparation method, DPPC, cholesterol, DSPE-PEG2000, DSPE-PEG2000-biotin film dispersion method is adopted to prepare the biotinylated liposome used for coating reporter DNA fragments, and the biotinylated liposome is taken as an immunolabelling biosensor. The invention also relates to a method used for detecting pancreas cancer marker REG1A based on the biotinylated liposome. The method comprises following steps: an ELSA plate is coated with REG1A murine monoclonal antibodies, a REG1A protein sample to be detected is added, reactions with REG1A rabbit source polyclonal antibodies, biotinylated goat anti rabbit IgG, and avidin are carried out respectively, at last the biotinylated liposome of an optimized concentration is added, fluorescence quantitative LAMP amplification is carried out, and the concentration of the REG1A protein is calculated based on amplification results. According to the preparation method, immunization LAMP reaction is combined with immunoliposome nano-particles, so that high sensitivity detection of pancreas cancer marker REG1A is realized, stability is high, cost is low, and the specificityis high.

Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.

The present invention relates to an immunoliposome preparation or a hydrophobic molecule-modified antibody having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome or a hydrophobic molecule-modified antibody comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.

The invention discloses an immune liposome based on Isthmin gene as well as a preparation method and application thereof. The immune liposome is formed by covalently combining a liposome encapsulated with an Isthmin recombinant eukaryotic expression vector and an antigen monoclonal antibody related to an anti-VIIIth factor. The preparation method comprises three steps of the preparation of the Isthmin recombinant eukaryotic expression vector, the encapsulation of the liposome of the Isthmin recombinant eukaryotic expression vector and the connection of the liposome encapsulated with the Isthmin recombinant eukaryotic expression vector and the antigen monoclonal antibody related to the anti-VIIIth factor. The immune liposome can actively target tumour neo-vascularization endothelial cells, release the Isthmin recombinant eukaryotic expression vector in the cells and express the Isthmin so as to play a role in anti-tumor angiogenesis. The invention has the advantages of effectiveness, low toxicity, simple preparation method and the like, and can be used for preparing medicaments for anti-tumor angiogenesis.

The invention relates to a manufacturing method and application of a nanoparticle biochip. The nanoparticle biochip is an immunoliposome compound nanoparticle biochip. The manufacturing method comprises the steps of: providing a substrate; letting the substrate surface and protein combine to form an active site by a surface treatment procedure; and carrying out reaction to make an antibody and theactive site to form a ligand receptor combination, thus obtaining the nanoparticle biochip.